Table 2:

Outcomes of patients who received ICI and developed AKI

	Patients with non-irAKI (N=109)	Patients with irAKI (N=14)	All Patients with AKI (N=123)	P Value Comparing non- irAKI to irAKI
Median Time to AKI (days)	91	71.5	89	0.4
Median Change in Cr from Baseline (mg/dL)	1.6	2.6	1.6	0.02
Magnitude of Change in Cr (Post-Treatment/Pre-Treatment)	2.6	4.0	2.7	0.02
Median Maximum Cr (mg/dL)	2.4	3.5	2.6	<0.01
Nephrology Consultation	26 (24%)	8 (57%)	34 (28%)	<0.01
CS Administered	8 (7%)	9 (64%)	18 (15%)	<0.01
Cr Improved with CS
Yes, to baseline	4 (50%)	5 (56%)	9 (7%)
Yes, not to baseline	0	2 (22%)	3 (2%)
No	4 (50%)	1 (11%)	5 (4%)
Unknown	0	1 (11%)	1 (1%)
Time Period to Improvement after CS	N=4	N=7	N=11
Within One Week	4 (100%)	5 (71%)	9 (82%)
Within One Month	0	2 (29%)	2 (18%)

AKI: acute kidney injury; Cr = creatinine; CS = corticosteroids; ICI = immune checkpoint inhibitor; ir = immune-related;